Management and Treatment of SARS-CoV-induced thrombotic events

Many thrombotic events have been related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), complicating clinical management of COVID-19 patients. This article details the biology, diagnosis, and therapy of the complex SARS-CoV-2-thrombotic illness relationship. This article begins by investigating how SARS-CoV-2 produces hypercoagulability. It explains how viral spike proteins produce endothelial dysfunction, coagulation cascade, and microvascular and macrovascular thrombi. Virus-induced systemic inflammation increases thrombotic risks by dysregulating the immune system and secreting cytokines. This article delves into the epidemiology of COVID-19 thrombotic events, examining data from clinical trials and observational research that explains rates of occurrence, risk factors, and outcomes. This finding highlights the fact that thrombotic problems can manifest differently in various patient groups, such as those with preexisting conditions, those in need of critical care, and those experiencing the long-term effects of SARS-CoV-2 infection. Thrombotic event management with concurrent COVID-19 therapies, including antiviral medications and immunomodulatory medicines, is also covered in the article. It discusses the interplay between these treatments and anticoagulation therapy, providing insights into optimizing management strategies to minimize both thrombotic and bleeding complications. Finally, the article emphasizes the need for ongoing research to further elucidate the mechanisms of SARS-CoV-2-induced thrombosis and to refine therapeutic strategies. It advocates for a multidisciplinary approach to managing thrombotic events, incorporating insights from infectious disease specialists, hematologists, and intensivists to improve patient outcomes.